Table 2 Treatment and outcomes of the participants
Characteristics | Total (n = 854) | SNUH (n = 101) | CODA (n = 110) | KOCOSS (n = 325) | KOLD (n = 318) |
|---|---|---|---|---|---|
Treatment | |||||
ICS/LABA use: yes (%) | 544/836 (65.1) | 53/91 (58.2) | 20 (18.2) | 201/317 (63.4) | 270 (84.9) |
ICS/LABA MPR, mean (SD) | 0.52 (0.44) | 0.44 (0.43) | 0.13 (0.32) | 0.49 (0.42) | 0.70 (0.39) |
LAMA use: yes (%) | 564/830 (68.0) | 61/91 (67.0) | 39 (35.5) | 250/311 (80.4) | 214 (67.3) |
LAMA MPR, mean (SD) | 0.54 (0.43) | 0.50 (0.43) | 0.26 (0.40) | 0.66 (0.39) | 0.53 (0.43) |
Severe acute exacerbation (%) | 81/854 (9.4) | 6/101 (5.9) | 6/110 (5.5) | 39/325 (12.0) | 30/318 (9.4) |